Business
Hoth Therapeutics, Inc. Announces Notice of Allowance for a New Patent Application Related to A Method for Inhibiting Formation of a Biofilm
NEW YORK, April 5, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"NEW YORK, April 5, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a patient-focused clinical-stage biopharmaceutical company, today announced that the Brazilian Patent Office has issued a notice of allowance for a patent application related to the Company's method for inhibiting formation of biofilms. The notice of allowance was issued March 31, 2021 and is related to a new patent application not previously announced.\n\n \n \n \n \n \n \n\n \n\"We are pleased to have been granted this additional patent by the Brazilian government for our novel method for inhibiting the formation of biofilms,\" said Robb Knie, CEO of Hoth Therapeutics. \"We have continued to expand our intellectual property portfolio related to these global underserved markets, where our novel therapeutics can be applied.\"\nResearchers at the University of Cincinnati discovered that an in vitro method for inhibiting formation of a biofilm comprising bacteria, the method comprising contacting the bacteria with a zinc chelator, wherein the bacteria comprise a zinc adhesion module and wherein the bacteria are selected from the group consisting of Staphylococcus epidermidis and Staphylococcus aureus and combinations thereof, whereby formation of the biofilm is inhibited; characterized in that the zinc chelator comprises DTPA at a concentration of from 20 μM to 2 mM. \nAbout Hoth Therapeutics\nHoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth's pipeline development is focused to improve the quality of life for patients suffering from indications including atopic dermatitis, skin toxicities associated with cancer therapy, chronic wounds, psoriasis, asthma, acne, mast-cell derived cancers & anaphylaxis and pneumonia. Hoth has also entered into two different agreements to further the development of two therapeutic prospects to prevent or treat COVID-19.\nForward-Looking Statement\nThis press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's bu...